Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeladon Pharmaceuticals Regulatory News (CEL)

  • This share is currently suspended. It was suspended at a price of 13.40
  • There is currently no data for CEL

Holding(s) in Company

20 Dec 2007 16:57

Celsis International PLC20 December 2007 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES (1). Identity of the issuer or the underlying issuer of existing shares to whichvoting rights are attached: Celsis International Plc 2. Reason for the notification (please state Yes/No): ( ) An acquisition or disposal of voting rights: (Yes) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( No) An event changing the breakdown of voting rights: ( No) Other (please specify) : ( ) 3. Full name of person(s) subject to the notification obligation: Loeb Partners Corporation 4. Full name of shareholder(s) (if different from 3.): (as above) 5. Date of the transaction and date on which the threshold is crossed or reachedif different): 19 December 2007 6. Date on which issuer notified: 20 December 2007 7. Threshold(s) that is/are crossed or reached: 3% 8. Notified details: A: Voting rights attached to shares Class/type of shares Situation previous to if possible using the the Triggering ISIN CODE transaction Number of shares Number of voting Rights GB00B0CD5F69 607,500 607,500 Resulting situation after the triggering transaction Class/type of shares Number of shares Number of voting rights % of voting rights if possible using the ISIN CODE Direct Direct Indirect Direct Indirect GB00B0CD5F69 757,500 757,500 - 3.43% B: Financial Instruments Resulting situation after the triggering transaction Type of Expiration Date Exercise/Conversion Number of voting % of voting financial Period/ Date rights that may be rights instrument acquired if the instrument is exercised/ converted. N/A Total (A+B)Number of voting rights % of voting rights 757,500 3.43% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: N/A Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold voting rights: 13. Additional information: 14. Contact name: Michael Emanuel 15. Contact telephone number: +1 212 483 7047 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Aug 20257:00 amRNSCancellation - Celadon Pharmaceuticals Plc
5th Aug 20256:00 pmRNSCeladon Pharmaceuticals
28th Jul 20254:10 pmRNSResult of General Meeting
2nd Jul 20257:00 amRNSProposed Cancellation
1st Jul 202511:48 amRNSFunding Update
1st Jul 20258:20 amRNSResult of AGM
1st Jul 20257:30 amRNSSuspension - Celadon Pharmaceuticals Plc
30th Jun 20257:00 amRNSFunding and Operational Update, Delay in Results
11th Jun 20257:00 amRNSNew Committed Credit Facility
6th Jun 20253:55 pmRNSFunding Update, Notice of AGM
30th May 20256:07 pmRNSFunding Update
30th Apr 20257:00 amRNSFunding Update
8th Apr 20253:05 pmRNSTermination of Facility
31st Mar 20253:15 pmRNSFunding Update
24th Mar 20257:00 amRNSBoard Changes and De-Listing Proposal
19th Mar 20257:00 amRNSFunding Update
26th Feb 20251:00 pmRNSNew Committed Credit Facility
12th Feb 20257:00 amRNSFinance Update
31st Jan 20257:00 amRNSFinance Update
16th Jan 20257:00 amRNSUpdate on Strategic Collaboration
2nd Jan 20257:00 amRNSFunding Update
20th Dec 20247:00 amRNSFinance Update
6th Dec 20247:00 amRNSReceipt of Subscription Proceeds
18th Nov 20247:00 amRNSUpdate on Financial Position
2nd Oct 20247:00 amRNSNew Sales Contract with a Healthcare Company
30th Sep 20247:05 amRNSDeparture of Chief Financial Officer
30th Sep 20247:00 amRNSInterim Results
17th Sep 20249:28 amRNSAdmission of Shares and Total Voting Rights
11th Sep 20247:05 amRNSEquity Fundraise and Update on Financial Position
11th Sep 20247:00 amRNSStrategic collaboration with Valeos
23rd Aug 20247:00 amRNSUpdate on Financial Position
12th Aug 20247:00 amRNSUpdate on Operations and Financial Position
16th Jul 20247:00 amRNSSuccessful Completion of Eighth Harvest of 2024
15th Jul 20241:58 pmRNSThird Admission of Shares
28th Jun 20247:00 amRNSResult of AGM
7th Jun 20247:00 amRNSSecond Admission of Shares
3rd Jun 20245:45 pmRNSPublication of Annual Report & Notice of AGM
23rd May 20247:00 amRNSSupply of Products to New US Customer
15th May 20242:45 pmRNSExercise of Share Options and Total Voting Rights
14th May 20247:00 amRNSFinal Results
10th May 20247:00 amRNSFundraise, RCF Extension, Termination of CLN & TVR
7th Mar 20247:00 amRNSEarly Economic Analysis of Feasibility Study Data
14th Dec 20237:00 amRNSProduct Supplied to First Two Sales Contracts
12th Dec 20232:00 pmRNSFundraise, Update on Future CLN Financing & TVR
16th Nov 20237:00 amRNSNew European Sales Contract
13th Oct 20237:00 amRNSFundraise, CLN Issue, Joint Broker Appointed & TVR
28th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSNotice of Results and Investor Presentation
5th Sep 20237:00 amRNSNew Sales Contract with UK Pharmaceutical Company
1st Aug 20237:00 amRNSApproval to roll-out chronic pain clinical trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.